Oxycodone Depot Teva Sweden (Oxycodone Hydrochloride)

Oxycodone Depot Teva Sweden is an opioid analgesic that acts on the central nervous system to relieve pain.

• Chronic cancer pain: Provides continuous, long‑acting relief for patients with persistent cancer‑related pain.
• Post‑surgical pain: Offers extended analgesia after major surgery when oral dosing intervals need to be minimized.
• Severe non‑cancer chronic pain: Delivers sustained pain control for conditions such as severe osteoarthritis or neuropathic pain unresponsive to other treatments.

• Oxycodone Hydrochloride binds primarily to μ‑opioid receptors in the brain and spinal cord, activating inhibitory G‑protein pathways that reduce neuronal excitability and diminish the perception of pain. This receptor activation also modulates neurotransmitter release, contributing to its analgesic effect.

Adverse reactions to Oxycodone Depot may vary in frequency and severity.

Common Side Effects

• Constipation: Reduced gastrointestinal motility leading to hard stools.
• Nausea: Sensation of queasiness, sometimes accompanied by vomiting.
• Drowsiness: Generalized sedation or feeling of fatigue.
• Dry mouth: Decreased salivary flow causing oral discomfort.
• Dizziness: Light‑headed sensation, especially when standing quickly.
• Itching: Mild pruritus, often localized.

Serious or Rare Side Effects

• Respiratory depression: Markedly slowed breathing that can be life‑threatening.
• Severe hypotension: Dangerous drop in blood pressure.
• Opioid use disorder: Development of dependence or addiction.
• Seizures: Uncommon but possible neurologic events.
• Anaphylaxis: Acute allergic reaction with airway compromise.
• adrenal insufficiency: Rare hormonal imbalance affecting stress response.

When prescribing Oxycodone Depot, clinicians should evaluate patient history and monitor for potential complications.

• Assess tolerance: Verify the patient’s prior opioid exposure and adjust expectations.
• Monitor respiratory function: Observe for signs of slowed breathing, especially after dose initiation.
• Evaluate liver and kidney function: Adjust use in patients with hepatic or renal impairment.
• Avoid concurrent CNS depressants: Limit use with alcohol, benzodiazepines, or other sedatives.
• Educate on dependence risk: Discuss signs of misuse and safe storage.
• Store at ambient temperature: keep the product in the original container, protected from moisture and direct sunlight.

Oxycodone Depot can interact with several medication classes, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Benzodiazepines: Combined use can cause profound respiratory depression and sedation.
• Central nervous system depressants: Concurrent alcohol or barbiturates markedly increase overdose risk.
• Monoamine oxidase inhibitors (MAOIs): May precipitate hypertensive crises or serotonin syndrome.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole): Can raise oxycodone plasma levels, requiring dose adjustment.
• CYP3A4 inducers (e.g., rifampicin): May reduce analgesic effect by increasing drug metabolism.
• Anticholinergic agents: May exacerbate constipation and urinary retention.
• Serotonergic drugs: Heightened risk of serotonin syndrome when combined with certain antidepressants.